RxDoctor Payments Data

Rosann Gregory

Physician Assistant · Maspeth, NYNPI 1073743431

Payments from drug & device makers

$2,803in general payments, 2019–2025

Across 47 payments — averaging $59.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$882
  • Abiomed$354
  • Abbott$341
  • AstraZeneca$289
  • Boehringer Ingelheim$244
  • E.r. Squibb & Sons, L.L.C.$125
  • plus $568 from 12 others

What the payments were for

  • Travel & lodging$48317%
  • Food & beverage$2,32083%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,803 in reported general payments places this provider in the 85th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$20,265
Medicare patients
330
Services billed
410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban56$72,581
XareltoRivaroxaban53$54,964
EntrestoSacubitril/Valsartan21$29,606
JardianceEmpagliflozin31$28,349
Repatha SureclickEvolocumab13$12,625
Ezetimibe77$2,293
Atorvastatin Calcium178$1,683
Nebivolol Hcl18$1,412
Rosuvastatin Calcium90$1,254
Metoprolol Succinate98$1,215
Prasugrel Hcl16$1,130
Diltiazem 24hr Er (Cd)Diltiazem Hcl25$906
Nifedipine ErNifedipine14$490
Amlodipine Besylate58$400
Ramipril28$372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$65$72,58156 claims
Johnson & JohnsonXarelto$73$54,96453 claims
NovartisEntresto$51$29,60621 claims
Boehringer IngelheimJardiance$244$28,34931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Maspeth

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →